Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
2024年1月2日 - 9:00PM
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field
of cellular metabolism pioneering therapies for rare diseases,
today announced that the company is scheduled to present at the
42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January
10, 2024, at 7:30 a.m. PT.
A live webcast of the presentation can be accessed under "Events
& Presentations" in the Investors section of the company's
website at www.agios.com. A replay of the webcast will be archived
on the company’s website for at least two weeks following the
presentation.
About AgiosAgios is the pioneering leader in PK
activation and is dedicated to developing and delivering
transformative therapies for patients living with rare diseases. In
the U.S., Agios markets a first-in-class pyruvate kinase (PK)
activator for adults with PK deficiency, the first
disease-modifying therapy for this rare, lifelong, debilitating
hemolytic anemia. Building on the company's deep scientific
expertise in classical hematology and leadership in the field of
cellular metabolism and rare hematologic diseases, Agios is
advancing a robust clinical pipeline of investigational medicines
with programs in alpha- and beta-thalassemia, sickle cell disease,
pediatric PK deficiency and MDS-associated anemia. In addition to
its clinical pipeline, Agios is advancing a preclinical TMPRSS6
siRNA as a potential treatment for polycythemia vera, and a
preclinical PAH stabilizer as a potential treatment for
phenylketonuria (PKU). For more information, please visit the
company’s website at www.agios.com.
Contacts:
Investor ContactChris Taylor, VP, Investor
Relations and Corporate CommunicationsAgios
PharmaceuticalsIR@agios.com
Media Contact Dan Budwick1AB dan@1abmedia.com
Agios Pharmaceuticals (NASDAQ:AGIO)
過去 株価チャート
から 4 2024 まで 5 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
過去 株価チャート
から 5 2023 まで 5 2024